The US Patent and Trademark Office has issued MAP Pharmaceutical Inc’s new drug under the banner, “Method of Therapeutic Administration of DHE to Enable Rapid Relief of Migraine while Minimizing Side Effect Profile.”
Pulmonary Administration DHE from MAPP Issued Patent (1)
The drug’s primary ingredient DHE or Dihydroergotamine is MAPP’s proprietary formulation. The novelty of this new formulation is that it has proved to have rapid efficacy in curbing migraine pain but minimizes the adverse effects that other migraine formulations have.
To be able to achieve quick distribution, metabolization and excretion of the drug, the DHE drug involves pulmonary administration or inhalation of the drug. This is advantageous as the results are almost instantaneous because the drug does not undergo a ‘first-pass effect’ and is absorbed almost entirely into the general blood circulation through the lungs.
The drug has been named LEVADEX® is an orally inhaled investigational drug administered using the Company’s proprietary TEMPO® inhaler for the potential acute treatment of migraine in adults and targets the pharmacokinetic profiles described in this patent. DHE is a drug that is currently available in other dosage forms to treat migraine. (2)
- Image from Ambro; Freedigitalphotos.net; February 2012; http://www.freedigitalphotos.net/images/view_photog.php?photogid=1499
- MAP Pharmaceuticals, Inc. (MAPP) Issued Additional U.S. Patent for Methods of Achieving Rapid Treatment of Migraine Based Upon Pharmacokinetic Profile; BioSpace; Febraury 2012; http://www.biospace.com/news_story.aspx?StoryID=250731&full=1
Copyrights apply to this blog. Please refer copyright permissions.